We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Procter & Gamble, Altria, Bristol-Myers, ConocoPhillips and Electronic Arts
Read MoreHide Full Article
For Immediate Release
Chicago, IL – August 02, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog includeProcter & Gamble (NYSE:(PG - Free Report) – Free Report), Altria (NYSE:(MO - Free Report) – Free Report), Bristol-Myers (NYSE:(BMY - Free Report) – Free Report), ConocoPhillips (NYSE:(COP - Free Report) – Free Report) and Electronic Arts (NASDAQ:(EA - Free Report) – Free Report).
Top Research Reports for Procter & Gamble, Altria & Bristol Myers
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (NYSE:(PG - Free Report) – Free Report), Altria (NYSE:(MO - Free Report) – Free Report) and Bristol-Myers (NYSE:(BMY - Free Report) – Free Report). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Buy-rated Procter & Gamble shares have outperformed the Zacks Consumer Staples sector in the past year (+4.8% vs. +2.1%). However, P&G shares have underperformed the S&P 500 index in the year-to-date period (up +8.1% vs. +10.5%).
P&G’s earnings and revenues surpassed expectations in fourth-quarter fiscal 2017. Adjusted earnings increased 8% year over year but net sales remained unchanged with the year-ago level.
The company has been struggling to boost market growth for the last few quarters. But the Zacks analyst likes the fact that P&G is speeding up innovations and investments to counter softening industry growth. Its productivity improvements and aggressive cost-saving efforts, projected to save $10 billion over the next five years, are also consistently helping to boost profit levels.
SharesofAltria have lagged the Zacks Tobacco industry in the year-to-date period, with the stock down -3.1% vs. the peer group’s +12.2% gain. Both Altria’s earnings and revenues grew year-over-year in the second quarter 2017 driven by strong cigarette pricing and increase in smokeless products.
Altria, the U.S.-based entity whose international sibling is Phillips Morris International (PM), is operating in a mature and heavily regulated market that has been undergoing consistent volume declines over the last many years. But the strength of Marlboro brand and a solid portfolio or low-risk smokeless tobacco products positions it to profitably navigate this market.
Further, the takeover of SABMiller by Anheuser-Busch InBev has helped Altria maximize the value of its SABMiller investment. An attractive dividend, currently yielding 3.8%, is a notable part of this story as well.
Bristol-Myers’s shares have underperformed the broader market as well as the large cap pharma group this year, losing -2.5% in the year-to-date period. Bristol-Myers delivered yet another strong quarter with the top and the bottom line beating expectations driven by sales of drugs like Opdivo, Eliquis and Yervoy.
Meanwhile, Bristol-Myers is looking to expand Opdivo’s label further which should boost performance. However, Opdivo is currently facing competitive challenges in the U.S. With the FDA approving Merck’s Keytruda, for the first-line treatment of metastatic nonsquamous NSCLC, the company is expected to see further loss of market share. Shares were down after Q2 results as concerns from AstraZeneca’s failed study on lung cancer drug Imfinzi loomed large on the company’s CheckMate 227 study on Opdivo.
Zacks' 2017 IPO Watch List Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Procter & Gamble, Altria, Bristol-Myers, ConocoPhillips and Electronic Arts
For Immediate Release
Chicago, IL – August 02, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog includeProcter & Gamble (NYSE:(PG - Free Report) – Free Report), Altria (NYSE:(MO - Free Report) – Free Report), Bristol-Myers (NYSE:(BMY - Free Report) – Free Report), ConocoPhillips (NYSE:(COP - Free Report) – Free Report) and Electronic Arts (NASDAQ:(EA - Free Report) – Free Report).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Tuesday’s Analyst Blog:
Top Research Reports for Procter & Gamble, Altria & Bristol Myers
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (NYSE:(PG - Free Report) – Free Report), Altria (NYSE:(MO - Free Report) – Free Report) and Bristol-Myers (NYSE:(BMY - Free Report) – Free Report). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Buy-rated Procter & Gamble shares have outperformed the Zacks Consumer Staples sector in the past year (+4.8% vs. +2.1%). However, P&G shares have underperformed the S&P 500 index in the year-to-date period (up +8.1% vs. +10.5%).
P&G’s earnings and revenues surpassed expectations in fourth-quarter fiscal 2017. Adjusted earnings increased 8% year over year but net sales remained unchanged with the year-ago level.
The company has been struggling to boost market growth for the last few quarters. But the Zacks analyst likes the fact that P&G is speeding up innovations and investments to counter softening industry growth. Its productivity improvements and aggressive cost-saving efforts, projected to save $10 billion over the next five years, are also consistently helping to boost profit levels.
(You can read the full research report on Procter & Gamble here >>>).
SharesofAltria have lagged the Zacks Tobacco industry in the year-to-date period, with the stock down -3.1% vs. the peer group’s +12.2% gain. Both Altria’s earnings and revenues grew year-over-year in the second quarter 2017 driven by strong cigarette pricing and increase in smokeless products.
Altria, the U.S.-based entity whose international sibling is Phillips Morris International (PM), is operating in a mature and heavily regulated market that has been undergoing consistent volume declines over the last many years. But the strength of Marlboro brand and a solid portfolio or low-risk smokeless tobacco products positions it to profitably navigate this market.
Further, the takeover of SABMiller by Anheuser-Busch InBev has helped Altria maximize the value of its SABMiller investment. An attractive dividend, currently yielding 3.8%, is a notable part of this story as well.
(You can read the full research report on Altria here >>>).
Bristol-Myers’s shares have underperformed the broader market as well as the large cap pharma group this year, losing -2.5% in the year-to-date period. Bristol-Myers delivered yet another strong quarter with the top and the bottom line beating expectations driven by sales of drugs like Opdivo, Eliquis and Yervoy.
Meanwhile, Bristol-Myers is looking to expand Opdivo’s label further which should boost performance. However, Opdivo is currently facing competitive challenges in the U.S. With the FDA approving Merck’s Keytruda, for the first-line treatment of metastatic nonsquamous NSCLC, the company is expected to see further loss of market share. Shares were down after Q2 results as concerns from AstraZeneca’s failed study on lung cancer drug Imfinzi loomed large on the company’s CheckMate 227 study on Opdivo.
(You canread the full research report on Bristol-Myers here >>>).
Other noteworthy reports we are featuring today include ConocoPhillips (NYSE:(COP - Free Report) – Free Report) and Electronic Arts (NASDAQ:(EA - Free Report) – Free Report).
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Get the full Report on PG – FREE
Get the full Report on MO - FREE
Get the full Report on BMY - FREE
Get the full Report on COP – FREE
Get the full Report on EA – FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.